As a ground breaking discovery, far Infrared treatments offer hope for individuals confronting chronic conditions who have not succeeded in finding ways to reverse their symptoms. Below is a 20 minute interview with CEO of Gladiator Therapuetics Bill Grovatt who offers a fascinating summary of the history behind using far infrared technology in new and innovative ways to treat a variety of chronic conditions.
For further information about the Gladiator Terapeutics technology visit:
https://gladiatortherapeutics.com
To order the far infrared devices visit:
Gladiator Therapeutics Devices
Gladiator Therapeutics Devices are designed to:
- Stimulate Healing
- Prevent Tissue Necrosis
- Increase Mitochondrial Function
- Improve Blood Flow
- Oxygenate Tissues
- Reduce inflammation
Implications for Chronic Conditions like Parkinsons
Gladiator’s far infrared Technology holds potential for chronic conditions by:
- Improving mitochondrial function
- Reduce neuroinflammation
- Enhance overall cellular health and function, which offers the opportunity to mitigate motor and non-motor symptoms
Research on Far Infrared treatments for Parkinsons
Curr Issues Mol Biol. 2023 Dec 6;45(12):9823-9837. Amelioration of Motor Performance and Nigrostriatal Dopamine Cell Volume Using a Novel Far-Infrared Ceramic Blanket in an A53T Alpha-Synuclein Transgenic Parkinson’s Disease Mouse Model
Abstract
We had attended a Parkinson’s Disease (PD) patient for a non-healing wound who reported a marked decrease in his hand tremor and freezing of gait when his wound was exposed to a ceramic far-field infrared (cFIR) blanket.
Efforts to slow or stop symptoms have resulted in the development and use of dopaminergic drug replacement therapy. Unfortunately, there is a loss of about 70-80% of substantia nigral dopaminergic neurons in patients by the time they are diagnosed with PD, and various dopaminergic drugs provide only temporary relief of their motor symptoms. There are limitations in treating PD with many conventional medications, necessitating a combination of pharmaceutical and non-pharmacological therapy as an essential adjunct to better address the health and welfare of PD patients.
We used male adult A53T alpha-synuclein transgenic mice exposed to a ceramic far-infrared blanket. Motor activity was assessed using the rotarod apparatus, and mouse brains were examined to quantify the fluorescence intensities of the immunostained samples. A53T alpha-synuclein transgenic mice had a significantly shorter time stay on the rotating bar than the wild-type mice (B6C3H). The rotarod performance was significantly improved in A53T alpha-synuclein transgenic mice exposed to cFIR as well as B6C3H healthy wild mice exposed to cFIR.
There was a significant statistical and substantive increase in the cellular composition of the Striatum and substantia nigra of cFIR-treated mice. Improvement in motor performance is seen in PD mice and wild mice and is associated with increases in cell volume in the substantia nigra and striatum after treatment.
Robert Rodgers PhD
Founder 2004
Parkinsons Recovery®
https://www.parkinsonsrecovery.com








